I-Mab Biopharma v. Inhibrx, Inc.

CourtDistrict Court, D. Delaware
DecidedOctober 1, 2024
Docket1:22-cv-00276
StatusUnknown

This text of I-Mab Biopharma v. Inhibrx, Inc. (I-Mab Biopharma v. Inhibrx, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
I-Mab Biopharma v. Inhibrx, Inc., (D. Del. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

I-MAB BIOPHARMA, ) ) Plaintiff, ) ) v. ) Civil Action No. 22-276-CJB ) INHIBRX, INC. and BRENDAN ) ECKELMAN, ) ) Defendants. )

Rodger D. Smith II and Anthony D. Raucci, MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, DE; Ching-Lee Fukuda, Tai-Heng Cheng and Vania Wang, SIDLEY AUSTIN LLP, New York, NY; Thomas A. Broughan III, SIDLEY AUSTIN LLP, Washington, DC; Brooke S. Böll, SIDLEY AUSTIN LLP, Los Angeles, CA; Erik B. Fountain, MCKOOL SMITH, P.C., Dallas, TX, Attorneys for Plaintiff.

Philip A. Rovner, Nicole K. Pedi, Tyler E. Cragg, Andrew M. Moshos and P. Andrew Smith, POTTER ANDERSON & CORROON LLP, Wilmington, DE; Amy H. Candido, WILSON SONSINI GOODRICH & ROSATI, P.C., San Francisco, CA, Attorneys for Defendants.

MEMORANDUM OPINION

October 1, 2024 Wilmington, Delaware Chedtyorier C) Punta In this case, Plaintiff ]-Mab Biopharma (“I-Mab” or “Plaintiff’) brings trade secret misappropriation claims against Defendants Inhibrx, Inc. (“Inhibrx”) and Brendan Eckelman (“Dr. Eckelman” and collectively with Inhibrx, “Defendants”). Presently pending before the Court are the following motions: (1) Defendants’ motion for summary judgment on Ground No. 6: Plaintiff is not entitled to enhanced damages or attorneys’ fees (the “Motion Regarding Ground No. 6”), (D.I. 352); and (2) Defendants’ motion for summary judgment on Ground No. 7: Plaintiff is not entitled to any damages for its claims of alleged misappropriation of Trade Secrets 6, 7, 9 and 10 (the “Motion Regarding Ground No. 7”), (D.I. 353).' I-Mab opposes the Motions. For the reasons set forth below, the Motion Regarding Ground No. 6 is DENIED and the Court will RESERVE DECISION on the Motion Regarding Ground No. 7.” I. BACKGROUND I-Mab commenced this action on March 1, 2022. (D.I. 2) The operative First Amended Complaint (“FAC”), filed on May 12, 2022, contains two causes of action, both for trade secret misappropriation against both Defendants: Count I, which alleges a violation of the federal Defend Trade Secrets Act (“DTSA”), and Count II, which alleges a violation of the Delaware Uniform Trade Secrets Act (“DUTSA”). (D.I. 49 at 9] 175-201) Plaintiff asserts that Defendants misappropriated nine trade secrets (that correspond to molecules designed to treat cancer) that are referred to herein as Trade Secret 1, Trade Secret 2, Trade Secret 4, Trade Secret

While Defendants also directed Motion Regarding Ground No. 7 to Trade Secret 3, that trade secret is no longer in the case. (See DI. 367 at 7 n.6; D.I. 408 at 15 n.14) 2 The parties have jointly consented to the Court’s jurisdiction to conduct all proceedings in this case, including trial, the entry of final judgment and all post-trial proceedings. (D.I. 89)

5, Trade Secret 6, Trade Secret 7, Trade Secret 8, Trade Secret 9 and Trade Secret 10. (See, e.g., D.I. 49 at ¶¶ 50, 59-70; D.I. 337, ex. 6 at 7-23) Defendants filed the instant Motions on June 14, 2024. (See D.I. 336) The Motions were fully briefed as of July 24, 2024. (D.I. 386) Trial is set for October 28, 2024. (D.I. 301 at 2)

The Court here writes primarily for the parties, and so any additional facts relevant to this Memorandum Opinion will be discussed in Section III below. II. STANDARD OF REVIEW The Court incorporates the legal standards regarding summary judgment set out in its September 19, 2024 Memorandum Opinion, (D.I. 408 at 3-4), and will make use of them in resolving the Motions. III. DISCUSSION The Court will take up each of Defendants’ two motions—which both relate to damages issues—in turn below. A. Motion Regarding Ground No. 6

The DTSA and DUTSA permit awards of exemplary damages and attorney’s fees if a trade secret was willfully and maliciously misappropriated. 18 U.S.C. § 1836(b)(3)(C)-(D); Del. Code tit. 6, §§ 2003(b), 2004.3 Defendants argue that they are entitled to summary judgment that Plaintiff is not entitled to exemplary damages or attorneys’ fees because there is no evidence that

3 While these statutes do not define the terms “willful” or “malicious[,]” Delaware courts assessing the issue of willful and malicious misappropriation pursuant to the DUTSA have defined willfulness as “an awareness, either actual or constructive, of one’s conduct and a realization of its probable consequences,” and malice as “ill-will, hatred or intent to cause injury.” Mattern & Assocs., L.L.C. v. Seidel, 678 F. Supp. 2d 256, 271 (D. Del. 2010) (quoting Nucar Consulting, Inc. v. Doyle, No. Civ.A. 19756-NC, 2005 WL 820706, at *14 (Del. Ch. Apr. 5, 2005)). 3 any alleged misappropriation was willful and malicious. (D.I. 336 at 27-28; D.I. 386 at 11-13) Plaintiff, for its part, responds that the evidence of record would support a finding of willfulness and maliciousness. (D.I. 367 at 24-27) Importantly, the issue of whether a defendant has acted willfully and/or maliciously is a

“highly fact-specific question best left to the jury.” PetroChoice Holdings, Inc. v. Orobono, Civil No. 2:19-cv-06152-JMG, 2022 WL 138008, at *6 (E.D. Pa. Jan. 14, 2022) (internal quotation marks and citations omitted) (citing cases).4 Indeed, Defendants’ opening brief devotes only two paragraphs to this motion, and in those two paragraphs Defendants simply cite to a handful of cases in which courts declined to award exemplary damages or attorneys’ fees following trial. (D.I. 336 at 27-28 (citing Roton Barrier, Inc. v. Stanley Works, 79 F.3d 1112, 1116, 1120-21 (Fed. Cir. 1996) (reversing the trial court’s finding of willful and malicious misappropriation that had followed a bench trial); Arnold’s Off. Furniture, LLC v. Borden, Civil No. 5:20-cv-05470-JMG 2023 WL 3851978, at *8, *11 (E.D. Pa. June 6, 2023) (declining the plaintiffs’ request for attorney’s fees based on the jury’s finding that the defendants’ conduct was

willful and malicious); AgroFresh Inc. v. Essentiv LLC, C.A. No. 16-662 (MN), 2020 WL 7024867, at *8, *26 (D. Del. Nov. 30, 2020) (denying the plaintiff’s request for exemplary damages, despite the jury having found that the defendants willfully and maliciously misappropriated the plaintiff’s trade secrets); Wayman Fire Prot., Inc. v. Premium Fire & Sec., LLC, C.A. No. 7866–VCP, 2014 WL 897223, at *17 (Del. Ch. Mar. 5, 2014) (concluding in

4 The Court notes that even if a fact finder concludes that willful and malicious misappropriation occurred, that does not mandate a finding that the prevailing party is entitled to exemplary damages or attorney’s fees. See Arnold’s Off. Furniture, LLC v. Borden, Civil No. 5:20-cv-05470-JMG, 2023 WL 3851978, at *10 (E.D. Pa. June 6, 2023). Rather, that decision lies within the Court’s sound discretion. AgroFresh Inc. v. Essentiv LLC, C.A. No. 16-662 (MN), 2020 WL 7024867, at *23 (D. Del. Nov. 30, 2020) (citations omitted). 4 post-trial findings of fact and conclusions of law that the plaintiffs were not entitled to exemplary damages or attorneys’ fees); Marsico v. Cole, Civ. A. No. 13104, 1995 WL 523586, at *8 (Del. Ch. Aug.15, 1995) (concluding post-trial that the defendant’s misappropriation was not malicious and therefore denying the plaintiff’s request for attorneys’ fees and exemplary damages))).5 Defendants have made only conclusory arguments in support of their Motion.

(D.I. 336 at 27-28) And Plaintiff has pointed to evidence that could support a finding of willfulness and maliciousness—such as evidence that Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Microstrategy, Inc. v. Business Objects, s.a.
429 F.3d 1344 (Federal Circuit, 2005)
Mattern & Associates, L.L.C. v. Seidel
678 F. Supp. 2d 256 (D. Delaware, 2010)
In re: Avandia Marketing v.
924 F.3d 662 (Third Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
I-Mab Biopharma v. Inhibrx, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/i-mab-biopharma-v-inhibrx-inc-ded-2024.